Advertisement
UK markets open in 3 hours 15 minutes
  • NIKKEI 225

    39,726.39
    +553.24 (+1.41%)
     
  • HANG SENG

    18,044.50
    -28.40 (-0.16%)
     
  • CRUDE OIL

    81.19
    +0.36 (+0.45%)
     
  • GOLD FUTURES

    2,332.20
    +1.40 (+0.06%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • Bitcoin GBP

    48,810.19
    +319.66 (+0.66%)
     
  • CMC Crypto 200

    1,284.18
    +35.06 (+2.81%)
     
  • NASDAQ Composite

    17,717.65
    +220.84 (+1.26%)
     
  • UK FTSE All Share

    4,493.07
    -21.69 (-0.48%)
     

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc.

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203